OLDSMAR, Fla.--(BUSINESS WIRE)--UVLrx Therapeutics announces that it has received CE marking to commercially sell its UVLrx 1500 multi-wavelength, intravenous light therapy system in the European Union. The UVLrx 1500 System offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths. Using the company’s patent pending Dry Light Adapter™ and a standard I.V. catheter, the UVLrx 1500 eliminates the need for removal of blood from the body.
UVLrx’s CE marking covers the following indications:
- Reduction of pain
- Reduction of pathogens in the blood
- Reduction of inflammation
- Immune system modulation
- Improved ATP synthesis
- Improved wound healing
- Improved blood oxygen transport
- Improved circulation
“We are pleased to have received the CE mark and are bringing the UVLrx 1500 System to the European market,” says Michael Harter, CEO and president of UVLrx. “The breadth of indications covered by our CE points to a bright future for this treatment and for the patients who will benefit from the technology.”
The UVLrx 1500 System is a LED-based medical device that administers multiple wavelengths through a peripheral I.V. catheter to the passing blood supply. Each wavelength was chosen as a result of its unique therapeutic qualities. Red light has anti-inflammatory and immune system-boosting capabilities, while green is shown to improve red blood cell function. UVA has a potent antimicrobial effect. Because skin inhibits the penetration of light, UVLrx delivers these wavelengths concurrently through a standard one-inch, 20-gauge I.V. catheter.
Once an I.V. site is established, the system calibration and setup take a matter of minutes. A patient sits comfortably during the 60-minute treatment, which includes 30 minutes of red and UVA wavelengths followed by 30 minutes of red and green wavelengths. For hospitals, outpatient surgery centers and private practice physicians, the UVLrx Treatment System seamlessly integrates with the standards of care for a variety of indications and conditions.
Ultraviolet Blood Irradiation has been used for over a century to treat bacterial and viral infections and was awarded a Nobel Prize for treating Lupus. Routinely used in hospitals worldwide, this form of light therapy fell out of prominence in the U.S. with the advent of antibiotics in the 1950s. With the recent expansion in drug-resistant infections, blood irradiation offers significant advantages to pharmaceutical therapies. The UVLrx 1500 Treatment System's innovations include multi-wavelength light delivery and a delivery system that requires only one intravenous entry point, eliminating requirements to remove and transfuse blood as well as the need for constant personnel supervision.
About UVLrx Therapeutics
Based in Oldsmar, Florida, UVLrx Therapeutics is dedicated to educating the world about the clinically proven benefits of the light wavelengths utilized in UVLrx technology. With its unique, multi-wavelength therapy system, UVLrx is executing its mission to provide safe and effective therapeutic solutions for a variety of medical issues. For more information on UVLrx, please visit www.uvlrx.com.
